New data from clinical trials highlight breakthroughs in immunotherapy for hard-to-treat cancers. The phase 2 TD-NICE trial shows favorable four-year outcomes combining tislelizumab with chemotherapy for esophageal squamous cell carcinoma, enhancing survival in neoadjuvant treatment. Separately, Anocca AB raised $46 million to fund its phase I trial of CRISPR-edited T-cell receptor (TCR) therapy targeting KRAS mutations in pancreatic cancer, advancing one of Europe’s first nonviral gene-edited TCR programs. These developments underscore the momentum in precision immunotherapy against historically resistant malignancies.